Search Results

There are 7637712 results for: content related to: Second primary melanomas on treatment with vemurafenib

  1. You have full text access to this OnlineOpen article
    A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma

    Pharmacology Research & Perspectives

    Volume 3, Issue 2, March 2015, Simone M. Goldinger, Jeannine Rinderknecht, Reinhard Dummer, Felix Pierre Kuhn, Kuo-Hsiung Yang, Lucy Lee, Ruben C. Ayala, Jagdish Racha, Wanping Geng, David Moore, Mei Liu, Andrew K. Joe, Selby Patricia Gil Bazan and Joseph F. Grippo

    Version of Record online : 2 FEB 2015, DOI: 10.1002/prp2.113

  2. You have free access to this content
    The use of vemurafenib in Australian patients with unresectable or metastatic melanoma containing the V600 BRAF gene mutation

    Asia-Pacific Journal of Clinical Oncology

    Volume 10, Issue S3, April 2014, Pages: 1–15, Michael P Brown and Georgina V Long

    Version of Record online : 8 APR 2014, DOI: 10.1111/ajco.12200

  3. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities

    British Journal of Dermatology

    Volume 167, Issue 5, November 2012, Pages: 987–994, R. Sinha, K. Edmonds, J.A. Newton-Bishop, M.E. Gore, J. Larkin and L. Fearfield

    Version of Record online : 29 OCT 2012, DOI: 10.1111/bjd.12010

  4. Developing melanoma therapeutics: overview and update

    Wiley Interdisciplinary Reviews: Systems Biology and Medicine

    Volume 5, Issue 3, May/June 2013, Pages: 257–271, John B. Korman and David E. Fisher

    Version of Record online : 13 FEB 2013, DOI: 10.1002/wsbm.1210

  5. You have free access to this content
    Society for Melanoma Research 2012 Congress

    Pigment Cell & Melanoma Research

    Volume 25, Issue 6, November 2012, Pages: 836–903,

    Version of Record online : 19 OCT 2012, DOI: 10.1111/pcmr.12023

  6. Improved human bioavailability of vemurafenib, a practically insoluble drug, using an amorphous polymer-stabilized solid dispersion prepared by a solvent-controlled coprecipitation process

    Journal of Pharmaceutical Sciences

    Volume 102, Issue 3, March 2013, Pages: 967–981, Navnit Shah, Raman M. Iyer, Hans-Juergen Mair, Duk Soon Choi, Hung Tian, Ralph Diodone, Karsten Fähnrich, Anni Pabst-Ravot, Kin Tang, Emmanuel Scheubel, Joseph F. Grippo, Sebastian A. Moreira, Zenaida Go, James Mouskountakis, Theresa Louie, Prabha N. Ibrahim, Harpreet Sandhu, Linda Rubia, Hitesh Chokshi, Dharmendra Singhal and Waseem Malick

    Version of Record online : 29 DEC 2012, DOI: 10.1002/jps.23425

  7. You have free access to this content
    Acute renal failure associated with the new BRAF inhibitor vemurafenib: A case series of 8 patients

    Cancer

    Volume 120, Issue 14, 15 July 2014, Pages: 2158–2163, Vincent Launay-Vacher, Sarah Zimner-Rapuch, Nicolas Poulalhon, Thibault Fraisse, Valérie Garrigue, Morgane Gosselin, Sabine Amet, Nicolas Janus and Gilbert Deray

    Version of Record online : 15 APR 2014, DOI: 10.1002/cncr.28709

  8. Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption

    Journal of Cutaneous Pathology

    Volume 41, Issue 6, June 2014, Pages: 539–543, Inbal Braunstein, Tara C. Gangadhar, Rosalie Elenitsas and Emily Y. Chu

    Version of Record online : 11 MAR 2014, DOI: 10.1111/cup.12318

  9. The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors

    Pigment Cell & Melanoma Research

    Volume 28, Issue 4, July 2015, Pages: 417–430, Casey G. Langdon, Matthew A. Held, James T. Platt, Katrina Meeth, Pinar Iyidogan, Ramanaiah Mamillapalli, Andrew B. Koo, Michael Klein, Zongzhi Liu, Marcus W. Bosenberg and David F. Stern

    Version of Record online : 6 MAY 2015, DOI: 10.1111/pcmr.12376

  10. Low-concentration vemurafenib induces the proliferation and invasion of human HaCaT keratinocytes through mitogen-activated protein kinase pathway activation

    The Journal of Dermatology

    Volume 42, Issue 9, September 2015, Pages: 881–888, Mi Ryung Roh, Jung Min Kim, Sang Hee Lee, Hong Sun Jang, Kyu Hyun Park, Kee Yang Chung and Sun Young Rha

    Version of Record online : 5 JUN 2015, DOI: 10.1111/1346-8138.12950

  11. Profile of vemurafenib-induced severe skin toxicities

    Journal of the European Academy of Dermatology and Venereology

    Volume 30, Issue 2, February 2016, Pages: 250–257, L. Peuvrel, G. Quéreux, M. Saint-Jean, A. Brocard, J.M. Nguyen, A. Khammari, A.C. Knol, E. Varey and B. Dréno

    Version of Record online : 2 NOV 2015, DOI: 10.1111/jdv.13443

  12. You have free access to this content
    Society for Melanoma Research 2014 Congress

    Pigment Cell & Melanoma Research

    Volume 27, Issue 6, November 2014, Pages: 1169–1241,

    Version of Record online : 23 OCT 2014, DOI: 10.1111/pcmr.12317

  13. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations

    British Journal of Dermatology

    Volume 173, Issue 4, October 2015, Pages: 1024–1031, R. Sinha, J. Larkin, M. Gore and L. Fearfield

    Version of Record online : 11 OCT 2015, DOI: 10.1111/bjd.13958

  14. You have free access to this content
    Society for Melanoma Research 2013 Congress

    Pigment Cell & Melanoma Research

    Volume 26, Issue 6, November 2013, Pages: 932–1019,

    Version of Record online : 24 OCT 2013, DOI: 10.1111/pcmr.12166

  15. Second primary melanomas treated with BRAF blockers: study by reflectance confocal microscopy

    British Journal of Dermatology

    Volume 168, Issue 6, June 2013, Pages: 1230–1235, S. Debarbieux, S. Dalle, L. Depaepe, N. Poulalhon, B. Balme and L. Thomas

    Version of Record online : 1 APR 2013, DOI: 10.1111/bjd.12210

  16. Vemurafenib oral bioavailability: An insoluble problem

    The Journal of Clinical Pharmacology

    Volume 54, Issue 4, April 2014, Pages: 375–377, Russell Z. Szmulewitz and Mark J. Ratain

    Version of Record online : 21 FEB 2014, DOI: 10.1002/jcph.277

  17. You have free access to this content
    2011 International Melanoma Congress

    Pigment Cell & Melanoma Research

    Volume 24, Issue 5, October 2011, Pages: 990–1075,

    Version of Record online : 10 OCT 2011, DOI: 10.1111/j.1755-148X.2011.00909.x

  18. You have full text access to this OnlineOpen article
    Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting

    Cancer Medicine

    Volume 4, Issue 8, August 2015, Pages: 1205–1213, Geoffrey T. Gibney, Geneviève Gauthier, Charles Ayas, Philip Galebach, Eric Q. Wu, Sarang Abhyankar, Carolina Reyes, Annie Guérin and Yeun Mi Yim

    Version of Record online : 20 MAY 2015, DOI: 10.1002/cam4.475

  19. Evaluation of drug supersaturation by thermodynamic and kinetic approaches for the prediction of oral absorbability in amorphous pharmaceuticals

    Journal of Pharmaceutical Sciences

    Volume 101, Issue 11, November 2012, Pages: 4220–4230, Shunsuke Ozaki, Ikuo Kushida, Taro Yamashita, Takashi Hasebe, Osamu Shirai and Kenji Kano

    Version of Record online : 28 AUG 2012, DOI: 10.1002/jps.23306

  20. Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma

    Journal of Cutaneous Pathology

    Volume 41, Issue 3, March 2014, Pages: 326–328, Penvadee Pattanaprichakul, Michael T. Tetzlaff, Whitney J. Lapolla, Carlos A. Torres-Cabala, Madeleine Duvic, Victor G. Prieto, Kenneth Y. Tsai and Jonathan L. Curry

    Version of Record online : 24 DEC 2013, DOI: 10.1111/cup.12273